Keytruda® (pembrolizumab) – Expanded indication
January 12, 2024 - Merck announced the FDA approval of Keytruda (pembrolizumab), in combination with chemoradiotherapy (CRT), for the treatment of patients with FIGO 2014 Stage III-IVA cervical cancer.
Download PDF
